16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Up to 50% of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (Abraxane®, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel.

          Related collections

          Author and article information

          Journal
          J. Urol.
          The Journal of urology
          Elsevier BV
          1527-3792
          0022-5347
          Aug 2011
          : 186
          : 2
          Affiliations
          [1 ] Department of Urology, Columbia University Medical Center, New York, New York 10032, USA.
          Article
          S0022-5347(11)03542-7
          10.1016/j.juro.2011.03.129
          21680003
          261c14b3-0904-4367-b41d-de239cac129f

          Comments

          Comment on this article